Suchergebnisse - "Guan, Xiuwen"

PubPharm (92)

11

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

enthalten in: Cancer innovation | 2022

von Guan, X. | Ma, F. | Xu, B.

12

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients

enthalten in: Cancer medicine | 2022

von Liu, B. | Yi, Z. | Guan, Y. | +10

13

Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer

enthalten in: Future oncology (London, England) | 2022

von Liu, B. | Guan, X. | Wang, Y. | +8

14

BERBERINE/MINERALIZED COLLAGEN COMPOSITE MEMBRANE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

enthalten in: Europäisches Patentamt | 2022

von ZHANG WEIFEN | ZHANG JIAN | ZHANG JINGJING | +4

15

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer : A study of the National Cancer Center, China

enthalten in: Breast (Edinburgh, Scotland) | 2022

von Li, Y. | Mo, H. | Guan, X. | +14

16

Selective thermotherapy of tumor by self-regulating photothermal conversion system

enthalten in: Journal of colloid and interface science | 2022

von Zhao, L. | Jiang, M. | Xu, Z. | +6

17

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy

enthalten in: Journal of advanced research | 2022

von Jiang, M. | Zhao, L. | Cui, X. | +5

18

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

enthalten in: Cancer Innovation | 2022

von Guan, X. | Ma, F. | Xu, B.

19

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

enthalten in: Cancer Medicine | 2022

von Liu, B. | Yi, Z. | Guan, Y. | +10

20

Antibody-drug conjugates in HER2-positive breast cancer

enthalten in: Chinese medical journal | 2021

von Li, L. | Zhang, D. | Liu, B. | +5